📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 14:17
12 analysed today
12
Today
133,654
All-time analysed
40,136
Positive
6,284
Negative
79,412
Neutral
7,754
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
31 announcements match the current filters (relevance ≥ 5).
Granules India Appoints Sanjay Kumar as CEO of Ascelis Peptides Effective Aug 13, 2026
Granules India has internally transferred its Chief Strategy Officer, Mr. Sanjay Kumar, to the role of CEO at its wholly-owned subsidiary, Ascelis Peptides Private Limited, effective August 13, 2026. This move provides dedicated leadership to the company's peptide and specialized segments, which are central to its 15-20% growth target. Ascelis Peptides is a critical but currently loss-making unit, having reported an EBITDA loss of INR 20 Cr. The transition follows Granules' significant investments in the space, including the INR 450 Cr acquisition of Senn Chemicals AG.
Confidence: HIGH
What changedThe Chief Strategy Officer of the parent company has been moved to lead a key growth subsidiary as its CEO.
Why it mattersIt signals a shift from group-level strategy to execution-focused leadership for the specialized peptide business, which is vital for margin expansion beyond base generics.
Ascelis EBITDA Loss: INR 20 CrSenn Chemicals Acquisition: INR 450 CrParent TTM Revenue: Rs 4474 CrEffective Date: August 13, 2026
📅 Short termThe market is likely to view this as a routine internal realignment with no immediate impact on the stock price.
📈 Long termIf successful, dedicated leadership at Ascelis could accelerate the company's transition into high-value CDMO and peptide markets, improving overall group ROCE.
⚠ Risk flags
- Execution risk in turning around a loss-making subsidiary
- Dependency on the success of the peptide portfolio for future margin growth
Key Highlights
Mr. Sanjay Kumar transitions from Group Chief Strategy Officer to CEO of Ascelis Peptides on August 13, 2026
Ascelis Peptides is a 100% wholly-owned subsidiary focused on the high-margin peptide portfolio
The parent company maintains a TTM revenue of Rs 4,474 Cr with a 21.6% operating margin
Management aims to address the INR 20 Cr EBITDA loss previously reported by the Ascelis unit
The move supports the integration of the INR 450 Cr Senn Chemicals acquisition into the CDMO vertical
👀 What to Watch
Monitor the next two quarterly results for Ascelis Peptides to see if dedicated leadership leads to a reduction in EBITDA losses and faster product filings.
60% PAT Growth in Q1 FY27; Complex Generics Reach 50% of Finished Dosages
Granules India reported its strongest Q1 ever, with revenue growing 22% YoY to ₹1,477 cr and PAT surging 60% to ₹180 cr. The company is successfully shifting its product mix, with complex generics now accounting for 50% of finished dosages, up from 39% a year ago. Financial health is robust with ROCE improving to 18% and the company becoming virtually debt-free with a Net Debt/EBITDA of 0.07x. Management confirmed that remediation at the Gagillapur facility is complete, with 9 product applications currently awaiting regulatory clearance to launch.
Confidence: HIGH
What changedThe company has successfully transitioned half of its finished dosage portfolio to complex generics and significantly deleveraged its balance sheet to near-zero net debt.
Why it mattersThe shift toward complex generics and Peptides (CDMO) improves margins and ROCE (now 18%), reducing the company's historical dependence on high-volume, low-margin commodity generics.
Q1 Revenue vs TTM Revenue: 33%PAT Growth (YoY): 60%Complex Generics Share: 50%Net Debt/EBITDA: 0.07xFormulation Capacity Addition: 40%ROCE: 18%
📅 Short termThe stock is likely to react positively to the significant earnings beat and the improvement in cash flow and debt metrics.
📈 Long termStructural shift toward innovation-led CDMO and complex generics provides a path for sustainable 15-20% growth and potential valuation re-rating.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory delay in Gagillapur clearance
- Litigation risks for first-to-file products
- Product concentration in top 5 molecules
Key Highlights
Revenue grew 22% YoY to ₹1,477 cr, representing approximately 33% of the previous TTM revenue in a single quarter.
PAT increased 60% YoY to ₹180 cr, supported by healthy gross margins of 65.6%.
Complex generics share of finished dosages rose to 50%, compared to 39% in the same quarter last year.
Peptide CDMO business (Senn Chemicals) delivered over 100% YoY growth, contributing CHF 5 million in Q1.
Generated ₹387 cr in operating cash flow during the quarter, reducing Net Debt/EBITDA to 0.07x.
👀 What to Watch
Monitor the US FDA's final clearance for the Gagillapur facility, which will unlock 9 pending product launches. Additionally, track the utilization ramp-up at the new Genome Valley facility, which adds 40% to total formulation capacity.
60% YoY PAT Growth to INR 1,800 Mn; Net Debt Reduced by INR 8,467 Mn in Q1 FY27
Granules India reported a robust Q1 FY27 with revenue increasing 22% YoY to INR 14,768 Mn, representing approximately 33% of TTM revenue. Net profit (PAT) surged 60% YoY to INR 1,800 Mn, supported by an improved EBITDA margin of 23% compared to 20% in the year-ago period. A significant highlight is the aggressive deleveraging, with net debt decreasing by INR 8,467 Mn YoY to just INR 1,012 Mn, resulting in a low Net Debt to EBITDA ratio of 0.07x. While North America remains the dominant market at 72% of revenue, the company is seeing growth in Europe and its new Peptides CDMO segment which now contributes 4% of revenue.
Confidence: HIGH
What changedGranules reported its Q1 FY27 results showing strong double-digit growth in revenue and profits alongside a massive reduction in debt.
Why it mattersThe significant jump in PAT and ROCE indicates improved operational efficiency and a successful shift toward higher-margin finished dosages and complex products, while the debt reduction strengthens the balance sheet for future expansions.
Revenue from Operations: INR 14,768 MnPAT: INR 1,800 MnNet Debt Reduction (YoY): INR 8,467 MnROCE: 18.0%Revenue vs TTM Revenue: ~33%Net Debt to EBITDA: 0.07x
📅 Short termThe stock is likely to react positively to the strong YoY profit growth and the significant improvement in the debt profile.
📈 Long termStructural improvements in ROCE and the growing contribution from the Peptides CDMO segment suggest a successful transition toward a more complex and margin-accretive product portfolio.
⚠ Risk flags
- High geographic concentration with 72% revenue from North America
- Management warning on supply chain volatility for the next two quarters
- Product concentration in top 5 molecules
Key Highlights
PAT grew 60% YoY to INR 1,800 Mn in Q1 FY27 compared to INR 1,126 Mn in Q1 FY26
Net debt saw a sharp reduction of INR 8,467 Mn from Q1 FY26 levels, standing at INR 1,012 Mn
Finished Dosages (FD) remains the core driver, contributing 74% of total revenue in Q1 FY27
ROCE improved to 18.0% in Q1 FY27 from 17.6% in the full year FY26
EBITDA margins expanded to 23% in Q1 FY27 from 20% in Q1 FY26, despite a 4% QoQ dip
👀 What to Watch
Watch the scaling of the Peptides CDMO business and the management's ability to navigate 'external cost pressures and supply chain volatility' mentioned for the next two quarters.
Granules Secures Sole First-to-File (FTF) Status for Sodium Oxybate ER Oral Suspension
Granules India has achieved Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension, the generic version of LUMRYZ®. This marks the company's second Sole FTF achievement, following its success with Amphetamine ER Tablets. Sole FTF status typically grants 180 days of market exclusivity in the U.S., which can lead to significantly higher margins and market share during the exclusivity period. This development aligns with Granules' strategy to transition from high-volume base generics to high-value complex generics.
Confidence: HIGH
What changedGranules has transitioned from a standard generic filer to a Sole First-to-File status holder for a complex, differentiated product in the U.S. market.
Why it mattersSole FTF status provides a temporary monopoly in the generic market, which is highly margin-accretive and helps diversify the company's revenue away from its top 5 commodity-like products.
Sole FTF ANDAs to date: 2Total Manufacturing Facilities: 11TTM Revenue: ₹ 4474 CrTTM Operating Profit Margin: 21.6%
📅 Short termThe announcement is likely to be viewed positively by the market as it validates the company's R&D pipeline and potential for high-margin U.S. sales.
📈 Long termThis reinforces Granules' structural shift toward complex generics and controlled substances, which is critical for long-term margin expansion and reducing pricing pressure from base generics.
⚠ Risk flags
- Potential patent litigation from the innovator (Alkermes)
- Regulatory compliance risks at manufacturing sites
- Execution risk in commercializing complex oral suspensions
Key Highlights
Secured Sole First-to-File (FTF) status for Sodium Oxybate Extended-Release for Oral Suspension.
Product is the generic equivalent of LUMRYZ®, used for treating cataplexy or excessive daytime sleepiness in narcolepsy patients.
This is the 2nd Sole FTF ANDA for the company, demonstrating increased R&D capability in complex generics.
Granules currently operates 11 manufacturing facilities across India, USA, and Switzerland to support its global portfolio.
👀 What to Watch
Investors should monitor the U.S. FDA's final approval timeline and the subsequent commercial launch date to gauge the timing of the 180-day exclusivity period's impact on earnings.
Granules India Receives USFDA EIR with VAI Status for Chantilly Facility
Granules India's US-based subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received an Establishment Inspection Report (EIR) from the USFDA for its facility in Chantilly, Virginia. The inspection, which took place from March 30 to April 3, 2026, resulted in a Voluntary Action Indicated (VAI) classification. Although four Form 483 observations were issued during the audit, the VAI status indicates that the facility is considered to be in a state of compliance. This clearance is vital for the company's continued manufacturing and supply operations within the United States.
Key Highlights
Received USFDA EIR for the Chantilly, Virginia facility with a VAI classification.
The inspection was conducted between March 30 and April 3, 2026.
Four Form 483 observations were issued during the inspection process.
The Chantilly facility is a wholly-owned subsidiary and a key component of Granules' global supply network.
👀 What to Watch
Investors should view this as a positive development as it resolves regulatory uncertainty regarding a key US manufacturing site. No immediate action is required, but this strengthens the company's compliance track record in regulated markets.
Granules India FY26 Revenue Hits ₹53,656 Mn; Gross Margin Rises to 65% on Complex Generic Shift
Granules India reported a strong FY26 with revenue growing 20% YoY to ₹53,656 million, crossing a major milestone. The company achieved record gross margins of 65%, up 355 basis points, driven by a strategic shift toward high-value complex generics. The newly acquired Senn Chemicals (Peptide CDMO) contributed ₹1,593 million in revenue and turned EBITDA positive in Q4. Despite ongoing regulatory remediation at the Gagillapur site, the company has maintained six consecutive quarters of sequential growth.
Key Highlights
FY26 revenue reached ₹53,656 million, a 20% YoY increase, driven by strong performance in North America and Europe.
Gross margins expanded to 65% due to improved product mix and the scaling of the Virginia (GPI) facility.
The US subsidiary (GPI) jumped to the 27th position among US generic companies by sales value, up from 74th in FY21.
Peptide CDMO vertical generated ₹1,593 million in FY26 revenue and achieved positive EBITDA in the final quarter.
Europe revenue grew 81% YoY, now contributing 15% of the total revenue base.
👀 What to Watch
Investors should focus on the upcoming US FDA re-inspection of the Gagillapur facility, as 9 pending product approvals are tied to its clearance. The successful turnaround of the peptide business and margin expansion provide a strong foundation for FY27 growth.
Granules India FY26 Net Profit Jumps 25.5% to ₹4,007 Million; Revenue Up 14.6%
Granules India reported a strong performance for the financial year ended March 31, 2026, with annual revenue growing 14.6% YoY to ₹34,739.60 million. The company's net profit for the full year saw a significant increase of 25.5%, reaching ₹4,006.67 million compared to ₹3,193.36 million in the previous fiscal. For the fourth quarter, revenue grew 14.1% YoY to ₹8,768.21 million. The company also demonstrated improved financial health by reducing its current borrowings from ₹8,081.93 million to ₹7,336.80 million.
Key Highlights
Annual Net Profit grew by 25.5% YoY to ₹4,006.67 million in FY26.
Total Revenue from operations for FY26 increased to ₹34,739.60 million from ₹30,301.63 million.
Q4 FY26 Revenue rose 14.1% YoY to ₹8,768.21 million compared to ₹7,680.26 million in Q4 FY25.
Full-year Earnings Per Share (EPS) improved to ₹16.48 from ₹13.17 in the previous year.
Current borrowings were reduced by ₹745.13 million during the fiscal year.
👀 What to Watch
The strong double-digit growth in both revenue and profitability, coupled with debt reduction, reflects high operational efficiency. Investors may consider this a positive signal for long-term value, though they should monitor the sustainability of margins in the competitive pharma sector.
Granules Q4FY26 PAT Jumps 33% YoY to INR 2,016 Mn; EBITDA Margins Expand to 24%
Granules India reported a strong Q4FY26 with revenue growing 23% YoY to INR 14,706 Mn and PAT increasing 33% YoY to INR 2,016 Mn. EBITDA margins saw a significant expansion to 24% from 21% in the previous year, driven by a better product mix and operational efficiencies. The company successfully reduced its net debt by INR 3,040 Mn over the year, bringing the Net Debt to EBITDA ratio down to a healthy 0.34x. Notably, the revenue share from Europe doubled to 17%, while the new Peptide/CDMO segment contributed 5% to the quarterly revenue.
Key Highlights
Q4FY26 Revenue grew 23% YoY to INR 14,706 Mn, while PAT rose 33% YoY to INR 2,016 Mn.
EBITDA margins expanded by 300 bps YoY to 24%, with EBITDA reaching INR 3,521 Mn (+40% YoY).
Net debt significantly reduced by INR 3,040 Mn YoY to INR 4,021 Mn; Net Debt/EBITDA stands at 0.34x.
Geographic diversification improved as Europe's revenue share rose to 17% from 8% YoY.
Full-year FY26 ROCE improved to 17.6% compared to 16.6% in the previous fiscal year.
👀 What to Watch
Investors should view these results positively due to the strong margin expansion and significant deleveraging of the balance sheet. The growth in the high-margin Peptide/CDMO segment and increased European market penetration provide a promising outlook for future earnings quality.
Granules India FY26 Revenue Hits ₹53,656 Mn, Up 20%; PAT Grows 19% to ₹5,950 Mn
Granules India achieved a significant milestone in FY26, surpassing ₹50,000 Mn in revenue with 20% YoY growth. The company witnessed structural margin expansion, with gross margins reaching 65% driven by a strategic shift toward Complex Generics, which now account for 43% of formulation sales. Financial health improved significantly as Net Debt to EBITDA dropped to 0.34x from 0.75x. The newly launched CDMO vertical and an 81% surge in European revenue emerged as key growth catalysts.
Key Highlights
FY26 Revenue grew 20% YoY to ₹53,656 Mn, surpassing the ₹50,000 Mn milestone for the first time.
Gross Margin expanded by 355 bps to 65.0%, while EBITDA grew 25% YoY to ₹11,851 Mn.
Complex Generics share in the Formulations segment increased to 43% from 31% in FY25.
Net Debt to EBITDA improved to 0.34x, supported by an equity infusion of ₹6,656 Mn.
Europe revenue grew by 81% YoY, and the new CDMO platform contributed ₹1,593 Mn in its first year.
👀 What to Watch
Investors should note the successful transition from volume-led to value-led growth through complex generics and CDMO services. The significant deleveraging and margin expansion provide a strong foundation for long-term capital appreciation.
Granules India FY26 PAT Jumps 25% to ₹4,007 Mn; Recommends ₹1.75 Final Dividend
Granules India reported a strong performance for the financial year ended March 31, 2026, with standalone revenue growing 14.6% YoY to ₹34,739.6 million. Net profit for the full year rose significantly by 25.5% to ₹4,006.67 million compared to ₹3,193.36 million in the previous year. The Board has recommended a final dividend of ₹1.75 per share, representing 175% of the face value. The company's balance sheet remains robust with total assets increasing to ₹59,812.79 million as of March 31, 2026.
Key Highlights
Full-year FY26 Revenue from operations increased to ₹34,739.60 million from ₹30,301.63 million in FY25.
Net Profit for FY26 grew by 25.5% YoY to ₹4,006.67 million.
Board recommended a final dividend of ₹1.75 per share (175%) for the financial year 2025-26.
Earnings Per Share (EPS) improved to ₹16.48 for the full year from ₹13.17 in the previous year.
Standalone Q4 FY26 revenue stood at ₹8,768.21 million, up from ₹7,680.26 million in the same quarter last year.
👀 What to Watch
Investors should view the strong double-digit growth in both revenue and profitability as a positive sign of operational scaling. The consistent dividend payout and improved EPS make it a healthy pick for long-term pharmaceutical sector exposure.
Granules India FY26 Net Profit Rises 25.5% to ₹4,007 Million; Revenue Up 14.6%
Granules India reported a robust performance for the full year ended March 31, 2026, with standalone revenue growing 14.6% YoY to ₹34,739.60 million. Net profit for the year surged by 25.5% to ₹4,006.67 million, reflecting improved operational efficiency and sales growth. For the fourth quarter, revenue stood at ₹8,768.21 million with a profit of ₹989.87 million. Additionally, the company successfully reduced its current borrowings to ₹7,336.80 million, indicating better cash flow management and a stronger balance sheet.
Key Highlights
Standalone Revenue for FY26 reached ₹34,739.60 million, a 14.6% increase over FY25's ₹30,301.63 million.
Net Profit for the full year grew to ₹4,006.67 million from ₹3,193.36 million in the previous year.
Annual Earnings Per Share (EPS) rose significantly to ₹16.48 from ₹13.17 YoY.
Current financial borrowings were reduced from ₹8,081.93 million to ₹7,336.80 million during the fiscal year.
Total Equity increased to ₹43,991.16 million as of March 31, 2026, compared to ₹34,030.10 million in the previous year.
👀 What to Watch
The strong double-digit growth in both top-line and bottom-line, coupled with effective debt reduction, reinforces the company's growth trajectory. Investors should view these results as a positive indicator of long-term value creation and operational stability.
Granules India Subsidiary Receives VAI Classification from US FDA for Shamirpet Facility
Granules India's wholly owned subsidiary, Granules Life Sciences, has received a Voluntary Action Indicated (VAI) classification from the US FDA for its Shamirpet facility in Telangana. The Establishment Inspection Report (EIR) follows a cGMP and pre-approval inspection conducted between December 15 and 19, 2025. The US FDA has officially closed the inspection with no regulatory actions recommended, providing a clear path for oral solid dosage manufacturing. This outcome enables multi-site manufacturing for approved products, enhancing the company's operational flexibility and supply chain reliability for the US market.
Key Highlights
US FDA issued an Establishment Inspection Report (EIR) with VAI classification for the Shamirpet manufacturing unit.
The inspection was conducted from December 15 to 19, 2025, covering oral solid dosage manufacturing operations.
The regulatory body has officially closed the inspection and recommended no further regulatory actions.
The clearance enables multi-site manufacturing capabilities for approved products across Granules' facility network.
Granules India maintains a global footprint with 11 manufacturing facilities, including 8 in India and 2 in the USA.
👀 What to Watch
This is a positive regulatory development that de-risks the company's manufacturing operations and supports future product launches. Investors should maintain confidence in Granules' compliance track record and its ability to service the regulated US market.
Granules India's US Packaging Facility Receives US FDA EIR with NAI Status
Granules India's US subsidiary, Granules Consumer Health, LLC, has received an Establishment Inspection Report (EIR) with 'No Action Indicated' (NAI) status from the US FDA. The inspection was conducted at its Manassas, Virginia packaging facility between December 1 and 3, 2025. This marks the second consecutive time the facility has cleared an FDA audit with zero observations, following a similar result in March 2023. The facility serves as a critical distribution hub for the company's US front-end OTC and prescription product operations.
Key Highlights
Received US FDA EIR with No Action Indicated (NAI) status for the Virginia packaging facility.
The inspection was conducted from December 1 to 3, 2025, resulting in zero observations.
Second consecutive successful FDA audit for this facility following the March 2023 inspection.
The site operates three advanced packaging lines for OTC and prescription (Rx) products.
Facility handles controlled substances and serves as a primary US distribution hub.
👀 What to Watch
This regulatory clearance confirms Granules' strong compliance culture and ensures no supply chain disruptions for its US OTC business. Investors should maintain a positive outlook on the stock given its consistent track record of zero-observation audits.
Granules India Allots Equity and Warrants Worth Rs 1,762.5 Cr at Rs 585/Share
Granules India has successfully allotted 51.28 lakh equity shares to institutional investors and 2.5 crore convertible warrants to the promoter group and select non-promoters. The allotment was priced at Rs 585 per share/warrant, with the company immediately raising Rs 300 crore from equity and Rs 365.6 crore as a 25% upfront warrant payment. This significant capital infusion, largely backed by the promoter group, indicates strong internal confidence and provides a substantial war chest for future growth. On a fully diluted basis, the total share capital will increase to 27.28 crore shares.
Key Highlights
Allotted 51,28,205 equity shares at Rs 585 each, raising Rs 300 crore from 360 ONE institutional funds.
Issued 2,50,00,000 convertible warrants at Rs 585 each, with 25% (Rs 365.62 crore) received upfront.
Promoter group subscribed to the majority of warrants, with Mrs. Chigurupati Uma Devi taking 2.48 crore warrants.
Total potential capital to be raised via warrants is Rs 1,462.5 crore within an 18-month conversion window.
Paid-up equity capital increased to Rs 24.78 crore and will reach Rs 27.28 crore on a fully diluted basis.
👀 What to Watch
Investors should view the promoter participation at Rs 585 as a strong signal of confidence in the company's valuation and future prospects. Monitor upcoming quarterly results for commentary on how this capital will be deployed for expansion or debt management.
Granules India to Issue 2.5 Cr Warrants and 51.28 Lakh Equity Shares via Preferential Issue
Granules India has received shareholder approval for a significant fundraise through a preferential issue of securities. The company plans to issue up to 2,50,00,000 convertible warrants and 51,28,205 equity shares to specific investors. The pricing will be subject to recomputation as per SEBI ICDR Regulations if required. Until the proceeds are fully utilized for their intended objects, the funds will be parked in low-risk instruments like debt mutual funds and government securities.
Key Highlights
Authorized issuance of up to 2,50,00,000 warrants convertible into equity shares
Authorized issuance of up to 51,28,205 equity shares on a preferential basis
Shareholder approval for the resolutions was obtained in the EGM held on January 22, 2026
Pricing of securities to be recomputed in compliance with SEBI ICDR Regulations where necessary
Unutilized proceeds to be temporarily invested in debt mutual funds, bank deposits, or government securities
👀 What to Watch
Investors should track the final allotment price and the specific end-use of funds to assess the long-term growth potential versus equity dilution. The move indicates a strong intent to raise capital for expansion or balance sheet strengthening.
Granules India Q3 FY26: Revenue Up 22% to ₹1,388 Cr, EBITDA Grows 34% with Margin Expansion
Granules India reported a strong Q3 FY26 with revenue growing 22% YoY to ₹1,388 crores, driven by robust performance in North America and Europe. EBITDA increased 34% to ₹308 crores, with margins expanding to 22.2% despite a ₹24.8 crore loss in the nascent Peptide CDMO segment. The company is making steady progress on regulatory remediation at its Gagillapur facility, following a constructive meeting with the US FDA in January 2026. Additionally, shareholders have approved a preferential issue to strengthen the balance sheet and fund future capacity expansions.
Key Highlights
Revenue grew 22% YoY to ₹1,388 crores, while EBITDA rose 34% to ₹308 crores.
Gross margins improved by 216 bps YoY to 63.9% due to a better product mix in finished dosages.
Gagillapur remediation is on track with no concerns raised by the FDA regarding the pace of corrective actions.
Net debt stood at ₹1,015 crores with a cash-to-cash cycle of 202 days.
Peptide CDMO business (Ascelis) is expected to see meaningful improvement in Q4 FY26 following project deliveries.
👀 What to Watch
Investors should monitor the final resolution of the Gagillapur warning letter and the commercial scale-up of the high-margin Peptide CDMO business. The company's focus on complex generics and integrated manufacturing continues to drive operational leverage.
Granules India Q3FY26: Revenue Up 22% YoY to ₹13,879 Mn, PAT Grows 28%
Granules India reported a strong Q3FY26 performance with revenue growing 22% YoY to ₹13,879 Mn, primarily driven by the Finished Dosage segment in North America and Europe. EBITDA margins expanded by 196 bps YoY to 22.2%, despite an EBITDA loss of ₹248 Mn from the Ascelis Peptides business. Net profit increased 28% YoY to ₹1,502 Mn, supported by a better product mix and scaling of the complex generics portfolio. The company maintained a healthy ROCE of 16.8% and reduced its Net Debt/EBITDA ratio to 0.91x.
Key Highlights
Revenue increased 22% YoY to ₹13,879 Mn, with Europe sales surging 131% YoY to ₹2,344 Mn.
EBITDA grew 34% YoY to ₹3,081 Mn, with margins improving to 22.2% from 20.2% in the previous year.
Finished Dosage (FD) segment continues to dominate, contributing 76% of total revenue.
Complex generics portfolio expanded, driven by the scale-up of the ADHD portfolio in the US market.
US Packaging facility completed FDA inspection with zero observations, and ANVISA Brazil GMP certificate was received for the Gagillapur site.
👀 What to Watch
The company's strategic shift toward complex generics and finished dosages is yielding higher margins and robust growth. Investors should maintain a positive outlook given the strong regulatory compliance record and expanding presence in high-value markets like Europe.
Granules India Q3FY26 PAT Rises 28% YoY to ₹1,502 Mn; EBITDA Margins Expand to 22.2%
Granules India reported a strong Q3FY26 with revenue growing 22% YoY to ₹13,879 Mn, primarily driven by the Finished Dosage segment in North America and Europe. EBITDA margins expanded by 196 bps YoY to 22.2%, despite an EBITDA loss of ₹248 Mn from the Ascelis Peptides business. Net profit increased 28% YoY to ₹1,502 Mn, supported by a better product mix and operational efficiencies. The company also received a credit rating upgrade from ICRA to AA and reported zero observations for its US packaging facility.
Key Highlights
Revenue increased 22% YoY to ₹13,879 Mn, led by 131% growth in the European market.
EBITDA grew 34% YoY to ₹3,081 Mn with margins improving to 22.2% from 20.2% last year.
Finished Dosage (FD) segment remains the primary driver, contributing 76% of total revenue.
ICRA upgraded the company's credit rating from AA- to AA, reflecting improved financial stability.
R&D investment stood at ₹689 Mn (5% of sales), focusing on complex generics and oncology.
👀 What to Watch
The stock shows strong fundamental growth with margin expansion and a successful shift towards high-margin complex generics. Investors should maintain a positive outlook while monitoring the break-even timeline for the Peptides business.
Granules India Q3FY26 PAT Rises 28% YoY to INR 1,502 Mn; Revenue Up 22%
Granules India reported a strong Q3FY26 performance with revenue growing 22% YoY to INR 13,879 Mn, primarily driven by the Finished Dosages segment in North America and Europe. Profitability improved significantly as EBITDA rose 34% YoY to INR 3,081 Mn, with margins expanding to 22% from 20% in the previous year. Net profit (PAT) increased 28% YoY to INR 1,502 Mn, reflecting efficient execution and vertical integration. The company maintains a healthy balance sheet with a Net Debt to EBITDA ratio of 0.91x and a ROCE of 16.8%.
Key Highlights
Revenue from operations grew 22% YoY to INR 13,879 Mn, led by Finished Dosages which contributes 76% of total revenue.
EBITDA increased 34% YoY to INR 3,081 Mn, with margins improving to 22%.
PAT grew 28% YoY to INR 1,502 Mn, showing strong bottom-line momentum.
Net Debt to EBITDA remains conservative at 0.91x with total net debt at INR 10,151 Mn.
ROCE stood at 16.8% post the acquisition of Senn Chemicals AG, compared to 16.4% YoY.
👀 What to Watch
The company's strong operational momentum and margin expansion in regulated markets like North America and Europe are positive indicators. Investors should monitor the scaling of the Peptides/CDMO segment and the continued integration of Senn Chemicals for long-term value.
Granules India Q3 FY26 Net Profit Rises 23.8% YoY to ₹1,115.8M; Plans ₹17,625M Fundraising
Granules India reported a 6.3% YoY increase in standalone revenue to ₹8,953.18 million for Q3 FY26, with net profit growing 23.8% to ₹1,115.82 million. The company is navigating challenges from a USFDA warning letter at its Gagillapur facility, which has led to higher remediation costs and production slowdowns. A significant fundraising plan of approximately ₹17,625 million through warrants and equity at ₹585 per share has been approved to support growth. Additionally, the company completed the acquisition of Granules Pharmaceuticals GmbH in Germany and accounted for costs related to the Senn Chemicals AG acquisition.
Key Highlights
Standalone Net Profit increased by 23.8% YoY to ₹1,115.82 million in Q3 FY26.
Total Revenue from operations grew 6.3% YoY to ₹8,953.18 million.
Approved fundraising of ₹14,625 million via convertible warrants and ₹3,000 million via equity at ₹585/share.
Exceptional item of ₹121.60 million recorded for Senn Chemicals AG acquisition costs.
Ongoing remediation at Gagillapur facility following USFDA warning letter continues to impact margins via higher consultancy and freight costs.
👀 What to Watch
Investors should monitor the progress of the USFDA remediation at the Gagillapur plant and the utilization of the ₹17,625 million fundraise. The growth in profit despite regulatory hurdles is a positive sign, but the high remediation costs remain a near-term drag.
